Physician profile
Barry Wein
NPI 1992776462
$2,236.05
in general payments reported to CMS, 2019-2025
22 companies · $595 in 2025
The $595 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $56.13 · 2022: $57.35 · 2023: $342 · 2024: $765 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,683 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,682.92 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $474.16 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $288.63 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $262.41 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $261.25 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $193.46 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $134.90 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $123.98 | 2024-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $105.31 | 2019-2025 | Shingrix, Arexvy |
| Eisai INC. | $83.02 | 2024-2025 | |
| Insightec,INC | $57.96 | 2024 | Exablate |
| Harmony Biosciences LLC | $32.63 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $26.87 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.94 | 2022 | |
| Amag Pharmaceuticals, INC. | $24.54 | 2019 | |
| Astellas Pharma US INC | $20.07 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $20.00 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Grifols USA, LLC | $18.71 | 2019 | |
| Biogen, INC. | $18.20 | 2024 | Leqembi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.54 | 2024 | Xifaxan |
| Exact Sciences Corporation | $16.24 | 2025 | The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Wein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.